In fact, from a study made in HepG2 human hepatoma cells using PCT 100 μM, it emerged that this bioactive molecule can inhibit lipogenesis by blocking key transcription factors and enzymes like sterol regulatory element-binding transcription factor 1 (SREBP-1), acetyl-CoA carboxylase (ACC), and PPARγ, leading to reduced TG accumulation [127]. The gene discussed is PPARG; the disease is hepatocellular carcinoma.